Opioid crisis education: The key to fixing pharma’s political and reputation problems?
As the opioid crisis continues to wreak havoc across the country, experts believe education may be the key to fixing pharma’s political and reputation problems.
Regulatory
CDC official stresses urgency of investigating vaping to Congress
The CDC’s principal deputy director said “hundreds” of new lung illness cases have been reported since last week.
What 5 states have done on vaping in one week
In the week since the Trump administration proposed banning flavored e-cigarettes, five states have taken action of their own.
What an 11-figure settlement could mean for Purdue Pharma
The lawsuits are set to go to trial next month.
Juul’s new marketing strategy doesn’t hold up to FDA scrutiny
The FDA sent its first warning letter to Juul after months of efforts to crack down on the company’s marketing tactics.
What politics has done to the healthcare industry’s reputation
The pharma industry fell dead last in Gallup’s latest industry reputation survey.
What’s next after J&J was found responsible for fueling Oklahoma’s opioid crisis
The company predicted its appeal could run through 2021.
FDA, brands caught in the middle of CBD legalization
CBD, or cannabidiol, is a non-psychoactive compound in cannabis. Some claim it has health benefits from easing pain to controlling anxiety, and many Americans are already using it.
Introducing Alison Kanski’s weekly column, Policy Deciphered
Policy Deciphered is a new weekly blog covering the goings-on in Washington.
Price-disclosure whiplash highlights breakneck pace
Pharma has been pulled in sometimes opposing directions as the push for drug-price reform moves at a breakneck pace.
Want to read more?
Please login or register first to view this content.
